Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial

Molecular Diagnosis and Therapy

Volumn 37, Issue 12, 2014, Pages 1211-1218

  Esteghamati, A ^a   Rezvani, S ^a   Khajeh, E ^a   Ebadi, M ^a   Nakhjavani, M ^a   Noshad, S ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Metformin; Pioglitazone; Randomized clinical trial; Type 2 diabetes; YKL 40

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARKER; METFORMIN; PIOGLITAZONE; UNCLASSIFIED DRUG; YKL 40; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CHI3L1 PROTEIN, HUMAN; LECTIN; HUMAN CARTILAGE GLYCOPROTEIN 39; PEPTIDES AND PROTEINS;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; TREATMENT OUTCOME; COMPARATIVE EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

ADIPOKINES; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LECTINS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84937629343     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40618-014-0154-x     Document Type: Article

References (36)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Eng J Med 339:229–234. doi:10.1056/NEJM199807233390404
2. Pyorala K, Laakso M, Uusitupa M (1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463–524
3. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE (2002) Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129–1134. doi:10.2337/diacare.25.7.1129
4. Gu K, Cowie CC, Harris MI (1998) Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care 21:1138–1145. doi:10.2337/diacare.21.7.1138
5. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143. doi:10.1161/hc0902.104353
6. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. New Eng J Med 352:1685–1695. doi:10.1056/NEJMra043430
7. Gustafson B (2010) Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 17:332–341
8. Stern MP (1995) Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes 44:369–374
9. Pradhan AD, Ridker PM (2002) Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 23:831–834. doi:10.1053/euhj.2001.3052
10. Festa A, D’Agostino R Jr, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131–1137
11. Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813–823
12. Rathcke C, Vestergaard H (2006) YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 55:221–227
13. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S (2007) Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18(391–396):3. doi:10.1097/MCA.1090b1013e328241d328991
14. Nøjgaard C, Høst NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS (2008) Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 19:257–263
15. Chu NV, Kong APS, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD (2002) Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25:542–549. doi:10.2337/diacare.25.3.542
16. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K (2003) Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493–2499. doi:10.2337/diacare.26.9.2493
17. American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36:S67–S74. doi:10.2337/dc13-S067
18. Cohen J (1988) Statistical power analysis for the behavioral sciences. L. Erlbaum Associates, Hillsdale
19. Volck B, Price PA, Johansen JS, Sørensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Phys 110:351
20. Rehli M, Krause S, Andreesen R (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43:221–225
21. Recklies AD, White C, Ling H (2002) The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365:119–126. doi:10.1042/bj20020075
22. Rathcke CN, Johansen JS, Vestergaard H (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 55:53–59. doi:10.1007/s00011-005-0010-8
23. Brix J-M, Höllerl F, Koppensteiner R, Schernthaner G, Schernthaner G-H (2011) YKL-40 in type 2 diabetic patients with different levels of albuminuria. Eur J Clin Inv 41:589–596. doi:10.1111/j.1365-2362.2010.02446.x
24. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H (2009) YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 32:323–328. doi:10.2337/dc08-1144
25. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbrüchel DA, Friis T, Bindslev L, Haack-Sørensen M, Jørgensen E, Kastrup J (2008) YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 42:295–302
26. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30:1066–1072
27. Boot RG, van Achterberg TAE, van Aken BE, Renkema GH, Jacobs MJHM, Aerts JMFG, de Vries CJM (1999) Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 19:687–694. doi:10.1161/01.atv.19.3.687
28. Rathcke CN, Vestergaard H (2009) YKL-40–an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8:61. doi:10.1186/1475-2840-8-61
29. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, Vestergaard H (2010) Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol 143:35–42. doi:10.1016/j.ijcard.2009.01.043
30. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the american diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetes Care 35:1364–1379. doi:10.2337/dc12-0413
31. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289. doi:10.1016/s0140-6736(05)67528-9
32. Belcher G, Matthews D (2000) Safety and tolerability of pioglitazone. Exp Clin Endocr Diabetes 108:S267–S273
33. Hempen M, Kopp HP, Elhenicky M, Hobaus C, Brix JM, Koppensteiner R, Schernthaner G, Schernthaner GH (2009) YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 19:1557–1563. doi:10.1007/s11695-009-9917-4
34. Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Rotellar F, Valenti V, Silva C, Gil MJ, Salvador J, Fruhbeck G (2011) Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. J Clin Endocr Metab 96:200–209. doi:10.1210/jc.2010-0994
35. Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plomgaard P, Krogh-Madsen R, Taudorf S, Lindegaard B, Pedersen BK (2008) Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 57:3078–3082. doi:10.2337/db08-0182
36. Thomsen SB, Rathcke CN, Skaaby T, Linneberg A, Vestergaard H (2012) The association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population. PLoS One 7:e47094. doi:10.1371/journal.pone.0047094